49 results about "Polio virus" patented technology

The invention relates to a multi-layer polytetrafluoroethylene composite film and protective material making method thereof. The method is characterized in that a polytetrafluoroethylene base band and a thermoplastic permeable film are drawn longitudinally together under the temperature of 100 to 200 DGE C and then are drawn widthwise together on an expander under the temperature of 50 to 300 DGE C and at last are sintered to stereotype under the temperature of 200 to 400 DGE C, in this way the multi-layer composite film is made. With the method of laminating, the composite film is made into a protective material with machine woven fabric, knitted fabric or non-woven fabric through bonds. The protective material has a steam permitting capability of 3000 to 12000g per square meters per 24 hours, a hydraulic pressure bearing capability of 50 to 220 thousand pa, the filtration efficiency for the microorganism in the air equal to or more than 99 percent, and the filtration efficiency of the polioviruses in liquid equal to or more than 99 percent. The capability of the invention does not impair after washing for a plurality of times. The protective material can be widely used as biochemical protection material, waterproof and permeable material, and windproof and warm keeping material.

The present invention is directed to non-pathogenic, oncolytic, recombinant polioviruses for the treatment of various forms of malignant tumors. The recombinant polioviruses of the invention are those in which the internal ribosomal entry site (IRES) of the wild type poliovirus was exchanged with the IRES of other picornaviruses, and optionally P1, P3 or the 3'NTR thereof was exchanged with that of poliovirus Sabin type. More particularly, the present invention is directed to the administration of the non-pathogenic, oncolytic, recombinant poliovirus to the tumor directly, intrathecally or intravenously to cause tumor necrosis. The method of the present invention is particularly useful for the treatment of malignant tumors in various organs, such as: breast, colon, bronchial passage, epithelial lining of the gastrointestinal, upper respiratory and genito-urinary tracts, liver, prostate and the brain. Astounding remissions in experimental animals have been demonstrated for the treatment of malignant glioblastoma multiforme, an almost universally fatal neoplasm of the central nervous system.

The invention relates to a fatty acid composition, which is diluted at normal temperature and in cold water to form solution used for cleaning of sterilization, fungicide and antivirus. The fatty acid composition comprises at least the following components: component A: food fatty acid comprising at least octyl decanoic acid and nonanoic acid; component B: surfactant comprising alkane sulfonate; component C: acid. The fatty acid composition has the advantages that the fatty acid composition or the diluted solution thereof has good stability, bactericidal and antiviral activity under the water temperature of 4-20 DEG C, no phase separation or crystallization, thus having safer use performance, and active components are low in cost, having more broad-spectrum bactericidal activity which can kill various bacteria, epiphytes and viruses. The fatty acid composition or the diluted solution thereof can be used for sterilization, fungicide and antivirus, which has high-efficient and quick killing effect; the sterilizing rate can reach more than 99.999 percent with contact time less than 1 minute; The fatty acid composition or the diluted solution thereof also has strong cleaning ability, and can keep effective even in hard water; the killing ratio for poliovirus reaches 99.9999 percent and the poliovirus can be killed immediately.

The present invention is directed to non-pathogenic, oncolytic, recombinant polioviruses for the treatment of various forms of malignant tumors. The recombinant polioviruses of the invention are those in which the internal ribosomal entry site (IRES) of the wild type poliovirus was exchanged with the IRES of other picornaviruses, and optionally P1, P3 or the 3'NTR thereof was exchanged with that of poliovirus Sabin type. More particularly, the present invention is directed to the administration of the non-pathogenic, oncolytic, recombinant poliovirus to the tumor directly, intrathecally or intravenously to cause tumor necrosis. The method of the present invention is particularly useful for the treatment of malignant tumors in various organs, such as: breast, colon, bronchial passage, epithelial lining of the gastrointestinal, upper respiratory and genito-urinary tracts, liver, prostate and the brain. Astounding remissions in experimental animals have been demonstrated for the treatment of malignant glioblastoma multiforme, an almost universally fatal neoplasm of the central nervous system.

The invention provides a multivalent immunogenic composition, which includes an inactivated hepatitis A antigen and an inactivated poliovirus. The composition also can further include over one or two of a purified pertussis antigen, diphtheria toxoid, tetanus toxoid, filamentous hemagglutinin, Haemophilus influenzae type b polysaccharide, Neisseria meningitidis capsular polysaccharide, a hepatitis B virus antigen, enterovirus 71 and a coxsackievirus A16 antigen, and a physiologically acceptable carrier. The composition involved in the invention is employed to immunize the inoculated population in the form of a bivalent vaccine or more combined vaccines. Without reducing the immune effects of each immunizing antigen, the inoculation number of times can be reduced at the same time, and the time and human resources can also be saved.

The invention discloses a virucidal disinfectant or preservative, comprising 45 - 65 wt% of at least one alcohol and 0.05 - 0.5 wt% of at least one phosphonate, and adjusting the pH to between 3 and 10. The disinfectant / preservative can be used for living or nonliving disinfection, and shows activity against a wide range of microorganisms, such as viruses, fungi and / or bacteria, especially naked viruses such as polio virus activity.

This specification is directed to nonlinear saccharide conjugates that comprise polysaccharides that are linked to at least two peptides that comprise T-cell epitopes and have no conformational B-cell epitopes where one of the peptides is linked to an internal saccharide so that the conjugates have a branched (i.e., nonlinear) structure. The specification also provides methods of manufacturing these conjugates, methods of formulating these conjugates in compositions for use as vaccines and methods of using the compositions to induce an immune response to the capsular saccharide. The specification also provides a new polyepitope carrier peptidecomprising the PV1 epitope from polio virus. The new polyepitope carrier peptidecan be used in both linear saccharide conjugates as well as the nonlinear saccharide conjugates.

The disclosure provides methods for poliovirus purification from crude cell culture harvests using a detergent followed by a clarification step.

The invention provides an attenuated polio virus having a 5′ non-coding region consisting of the 5′ non-coding region of Sabin 3, modified so that it does not have a base pair mismatch in stem (a) or (b) of domain V, wherein seven or eight of the base pairs in stems (a) and (b) are U-A or A-U base pairs; and a capsid protein from the Sabin 1, Mahoney, MEF or Saukett strain.

The invention provides a multivalent immunogenic composition, which includes an inactivated hepatitis A antigen and an inactivated poliovirus. The composition also can further include over one or two of a purified pertussis antigen, diphtheria toxoid, tetanus toxoid, filamentous hemagglutinin, Haemophilus influenzae type b polysaccharide, Neisseria meningitidis capsular polysaccharide, a hepatitis B virus antigen, enterovirus 71 and a coxsackievirus A16 antigen, and a physiologically acceptable carrier. The composition involved in the invention is employed to immunize the inoculated population in the form of a bivalent vaccine or more combined vaccines. Without reducing the immune effects of each immunizing antigen, the inoculation number of times can be reduced at the same time, and the time and human resources can also be saved.

The present invention provides monoclonal antibodies that recognize polio virus receptor (PVR) and inhibit its binding to T cell immunoreceptor with Ig and ITIM domains (TIGIT). The present invention further provides pharmaceutical compositions comprising the antibodies and methods for their use in cancer immunotherapy, treating infections and in diagnosis.

The invention relates to a gene chip for detecting food-home virus and a kit, belonging to the inspection field. The surface of a solid phase carrier is fixed with a plurality of detection probes and quality control contrast probes, wherein, the detection probes consist of the probes for detecting hepatitis A virus, human astrovirus, norwalk virus G1, norwalk virus G2, rotavirus, polio virus 1, polio virus 2 and polio virus 3; and the quality control contrast probes consist of a spotting positive quality control probe, a chip hybridization positive quality control probe and a chip negative quality control probe. The gene chip and the kit have the advantages of: (1) high throughout: five common viruses are integrated and detected simultaneously, and the practicability is strong; (2) rapidness: the detection time is only 4 hours; (3) specificity: the false positive caused by the cross reaction is avoided; (4) flexibility: the detection flexibility of the chip is 10<8> virus particles per gram of the tissue sample, which is higher than that of RT-PCR; and (5) good repetitiveness and stable results. The gene chip and the kit can be widely applied to the food safety inspection of the inspections system.